← All trials
NCT02869763
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2016
- Primary completion
- May 1, 2017
- Completion date
- May 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 12
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Institut Hospital del Mar d'Investigacions MèdiquesLead sponsor
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- Universidad Autonoma de BarcelonaStudy chair
- World Anti-Doping AgencyCollaborator
- Institut Hospital del Mar d'Investigacions MèdiquesReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.